02142.HK
HBM Holdings Limited
HKSE · Healthcare · Biotechnology · CN
HKD 14.72
−2.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 244.0M | 158.2M | 38.1M | 89.5M | 40.7M |
| Cost of Revenue | 19.0M | 11.1M | 4.5M | 2.0M | 130.0K |
| Gross Profit | 225.0M | 147.1M | 33.6M | 87.5M | 40.5M |
| Operating Expenses | |||||
| R&D Expense | 66.3M | 38.1M | 21.0M | 45.1M | 135.1M |
| SG&A Expense | 39.9M | 28.3M | 7.5M | 20.6M | 10.1M |
| General & Admin Expense | 631.0K | — | 4.9M | 19.5M | 10.1M |
| Selling & Marketing Expense | 2.4M | — | 2.7M | 1.1M | — |
| Other Expenses | 8.8M | — | 8.8M | — | 16.6M |
| Total Operating Expenses | 115.0M | 66.4M | 37.3M | 65.6M | 161.9M |
| Cost and Expenses | 134.0M | 77.5M | 41.8M | 67.7M | 162.0M |
| Operating Income (EBIT) | 110.0M | 80.7M | (3.7M) | 21.8M | (121.9M) |
| Non-Operating | |||||
| Interest Income | 4.8M | 12.2M | 6.8M | 5.6M | 2.9M |
| Interest Expense | 2.7M | 2.0M | 3.5M | 3.9M | 2.0M |
| Net Interest Income | 2.2M | 10.1M | 3.3M | 1.8M | 879.0K |
| Other Non-Op Income/Expense | 13.8M | 13.0M | 7.4M | 855.0K | (15.1M) |
| Non-Operating Income (excl Interest) | 12.5K | — | — | (4.7M) | 13.7M |
| EBT (Pre-Tax Income) | 123.8M | 93.7M | 3.7M | 22.7M | (137.0M) |
| Income Tax Expense | 2.0M | 1.3M | 997.0K | (81.0K) | 248.0K |
| Bottom Line | |||||
| Net Income | 121.6M | 91.5M | 2.8M | 22.8M | (137.3M) |
| Earnings from Cont. Ops | 121.8M | 92.4M | 2.7M | 22.8M | (137.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 121.6M | 91.5M | 2.8M | 22.8M | (137.2M) |
| Per Share | |||||
| Basic EPS | HK$0.15 | HK$0.12 | HK$0.00 | HK$0.03 | (HK$0.19) |
| Diluted EPS | HK$0.14 | HK$0.11 | HK$0.00 | HK$0.03 | (HK$0.19) |
| Revenue Per Share | HK$0.29 | HK$0.20 | HK$0.05 | HK$0.12 | HK$0.06 |
| Shares | |||||
| Basic Shares Outstanding | 836.7M | 791.5M | 768.2M | 742.5M | 729.4M |
| Diluted Shares Outstanding | 847.9M | 810.7M | 772.5M | 742.5M | 729.4M |
| Profitability Metrics | |||||
| EBITDA | 115.8M | 83.2M | (2.1M) | 31.2M | (130.2M) |
| D&A | 5.8M | 2.5M | 1.6M | 4.6M | 4.8M |
| EBIT | 110.0M | 80.7M | (3.7M) | 26.6M | (135.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026